Antithrombotic effect of a novel protein from Fusarium sp. CPCC 480097 in a rat model of artery-vein bypass thrombosis

Pharmaceutical Biology

Volumn 50, Issue 7, 2012, Pages 866-870

  Wu, Bin ^a,b   Xu, Jiaxing ^a  

^a NANJING TECH UNIVERSITY   (China)

^b NONE

Author keywords

anticoagulant; Fibrinogenolytic activity; S 2238; S 2765

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CHROMOGENIC SUBSTRATE; DEXTRO PHENYLALANYLPIPECOLYLARGININE 4 NITROANILIDE; FIBRINOGEN; FUNGAL PROTEIN; HEPARIN; PROTEIN FU P; S 2765; SODIUM CHLORIDE; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTITHROMBOTIC ACTIVITY; ARTERY VEIN BYPASS THROMBOSIS; ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SPECIFICITY; FIBRINOLYTIC THERAPY; FUSARIUM; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTEIN HYDROLYSIS; PROTHROMBIN TIME; RAT; THROMBIN TIME; THROMBOSIS; THROMBOSIS PREVENTION;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; FUNGAL PROTEINS; FUSARIUM; MALE; RATS; RATS, SPRAGUE-DAWLEY; THROMBOSIS;

FUSARIUM SP.; RATTUS;

EID: 84862003168     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2011.641023     Document Type: Article

References (26)

1. Bates SM, Weitz JI. (2006). The status of new anticoagulants. Br J Haematol, 134, 3-19. (Pubitemid 43830022)
2. Bin Wu, Licheng Wu, Daijie Chen, Zhijun Yang, Minyu Luo. (2009). Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097. J Ind Microbiol Biot, 36, 451-459.
3. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-254.
4. Butenas S, Mann KG. (2002). Blood coagulant. Biochemistry, 67, 5-15.
5. Chu AJ, Beydoun S, Mathews ST, Hoang JL. (2003). Novel anticoagulant polyethylenimine: Inhibition of thrombin-catalyzed fibrin formation. Arch Biochem Biophys, 415, 101-108. (Pubitemid 36687922)
6. Dahlbäck B. (2000). Blood coagulation. Lancet, 355, 1627-1632.
7. Drouet L. (1996). Fibrinogen: A treatable risk factor? Cerebrovasc Dis, 6, 2-6.
8. Frizzell JP. (2005). Acute stroke: Pathophysiology, diagnosis, and treatment. AACN Clin Issues, 16, 421-40.
9. Guglielmone HA, Agnese AM, Núñez Montoya SC, Cabrera JL. (2002). Anticoagulant effect and action mechanism of sulphated flavonoids from Flaveria bidentis. Thromb Res, 105, 183-188. (Pubitemid 34214936)
10. Hirsh J. (2003). Current anticoagulant therapy-unmet clinical needs. Thromb Res, 109, 1-8.
11. Howard SC, Algra A, Rothwell PM; (2008) Cerebrovascular cohort studies collaboration. Effect of age and glycaemic control on the association between fibrinogen and risk of acute coronary events after transient ischaemic attack or stroke. Cerebrovasc Dis, 25, 136-143. (Pubitemid 351280388)
12. Kannel WB. (1997). Influence of fibrinogen on cardiovascular disease. Drugs, 54, 32-40.
13. Kim MS, Lee KA. (2006). Antithrombotic activity of methanolic extract of Umbilicaria esculenta. J Ethnopharmacol, 105, 342-345.
14. Maksimenko AV, Tischenko EG, Golubykh VL. (1999). Antithrombotic activity of the superoxide dismutase-chondroitin sulfate complexes in a rat model of arterial injury. Cardiovasc Drugs Ther, 13, 479-484. (Pubitemid 30032254)
15. Motoyashiki T, Tu AT, Azimov DA, Ibragim K. (2003). Isolation of anticoagulant from the venom of tick, Boophilus calcaratus, from Uzbekistan. Thromb Res, 110, 235-241. (Pubitemid 37338299)
16. Nutescu EA. (2003). The future of anticoagulation clinics. J Thromb Thrombolysis, 16, 61-63.
17. Peng X, Huang WY. (2004). Clinical analysis of defibrase injection in treatment of acute cerebral infarction. China J Mod Med, 14, 36-38.
18. Philomene WK, Masao Y, Katsushito A, Chinzei Y. (1998). Purification and characterization of a thrombin inhibitor from the salivary glands of a malarial vector mosquito, Anopheles stephensi. Biochim Biophys Acta, 1381, 227-233.
19. Rosenberg RD, Rosenberg JS. (1984). Natural anticoagulant mechanisms. J Clin Invest, 74, 1-6. (Pubitemid 14086038)
20. Rothwell PM, Howard SC, Power DA. (2004). The cerebrovascular cohort studies collaboration: Fibrinogen concentration and risk of ischaemic stroke and acute coronary events in 5113 patients with transient ischaemic attack and minor ischaemic stroke. Stroke, 35, 2300-2305. (Pubitemid 39311253)
21. Tanne D, Benderly M, Goldbourt U. (2001). The bezafibrate infarction prevention study group: A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med, 111, 457-463. (Pubitemid 33016417)
22. Vlachopoulos C, Pietri P, Aznaouridis K, Vyssoulis G, Vasiliadou C, Bratsas A, Tousoulis D, Xaplanteris P, Stefanadi E, Stefanadis C. (2007). Relationship of fibrinogen with arterial stiffness and wave reflections. J Hypertens, 25, 2110-2116. (Pubitemid 47476309)
23. Voet D, Voet JG. (1990). Biochemistry. New York; Wiley; pp 87-1095.
24. Von Clauss A. (1957). Rapid physiological coagulant method in determination of fibrinogen. Acta Haematol, 17, 237-244.
25. Weitz JI. (2001). New anticoagulant drugs. J Thromb Thrombolysis, 12, 7-17.
26. Zingali RB, Jandrot-Perrus M, Guillin MC, Bon C. (1993). Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom: Characterization and mechanism of thrombin inhibition. Biochemistry, 32, 10794-10802. (Pubitemid 23327816)